Cancer chemotherapy in older adults. A tolerability perspective
- PMID: 9111706
- DOI: 10.2165/00002512-199710010-00004
Cancer chemotherapy in older adults. A tolerability perspective
Abstract
The incidence of cancer increases with age. Since the geriatric population is growing, we will be confronted with an increasing number of patients with cancer who are > 65 years of age. The purpose of this review is to address the use of cancer chemotherapy in older persons with respect to its tolerability. We performed a review of the literature using 'Medline' and the bibliographies of pertinent publications. Information about cancer treatment in older adults was extracted with particular attention to chemotherapy-related toxicity in patients aged > 65 years. Comorbid disease, polypharmacy/drug interactions, psychosocial issues and age-related physiological changes are major issues in caring for older patients with cancer. Since older individuals may have a greater number of comorbid illnesses, treatment should be initiated on the basis of physiological rather than chronological age. Comparative studies show that chemotherapy-related toxicity is similar in older and younger patients, with the exception of haematological toxicity, which may be more severe in older patients, and cardiotoxicity, which is more frequent in the elderly. Other evidence suggests that gastrointestinal and neurotoxicities may also be more severe in older individuals. The dosages of chemotherapeutic agents that are primarily renally excreted may require adjustment in older patients. Haematological reserve is decrease in older individuals, and drugs that cause myelosuppression must be used with care. The use of haemopoietic growth factors in geriatric patients is currently being investigated.
Similar articles
-
[Chemotherapy in the elderly].Gan To Kagaku Ryoho. 1992 Sep;19(11):1796-800. Gan To Kagaku Ryoho. 1992. PMID: 1519923 Japanese.
-
[Cancer chemotherapy in patients older than 75 years old--from the aspect of clinical pharmacology].Gan To Kagaku Ryoho. 1998 Jun;25(7):995-9. Gan To Kagaku Ryoho. 1998. PMID: 9644313 Review. Japanese.
-
The clinical toxicity of anticancer drugs and its prediction.Semin Oncol. 1977 Jun;4(2):147-63. Semin Oncol. 1977. PMID: 406677 Review. No abstract available.
-
Physiological aging in older adults with cancer: implications for treatment decision making and toxicity management.J Gerontol Nurs. 2010 Feb;36(2):26-37; quiz 38-9. doi: 10.3928/00989134-20091103-98. Epub 2010 Feb 5. J Gerontol Nurs. 2010. PMID: 19928710
-
The role of myelopoietic growth factors in managing cancer in the elderly.Drugs. 2002;62 Suppl 1:47-63. doi: 10.2165/00003495-200262001-00004. Drugs. 2002. PMID: 12479594 Review.
Cited by
-
Cardiovascular complications of breast cancer therapy in older adults.Oncologist. 2011;16(8):1138-43. doi: 10.1634/theoncologist.2010-0348. Epub 2011 Jul 7. Oncologist. 2011. PMID: 21737575 Free PMC article. Review.
-
Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.Oral Oncol. 2019 Sep;96:7-14. doi: 10.1016/j.oraloncology.2019.06.017. Epub 2019 Jul 3. Oral Oncol. 2019. PMID: 31422216 Free PMC article. Clinical Trial.
-
Drug dosage in the elderly. Is it rational?Drugs Aging. 1998 Nov;13(5):357-79. doi: 10.2165/00002512-199813050-00003. Drugs Aging. 1998. PMID: 9829164 Review.
-
Strategies for improving quality of life in older patients with metastatic breast cancer.Drugs Aging. 2002;19(8):605-22. doi: 10.2165/00002512-200219080-00006. Drugs Aging. 2002. PMID: 12207554 Review.
-
Prevalence of and Risk Factors for Drug-Related Readmissions in Older Adults: A Systematic Review and Meta-Analysis.Drugs Aging. 2024 Jan;41(1):1-11. doi: 10.1007/s40266-023-01076-8. Epub 2023 Oct 21. Drugs Aging. 2024. PMID: 37864770 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources